Correlative Analysis of RARα1/α2-PML mRNA Expression and On-Study Clinical Characteristics
| Characteristic or Category . | RARα-PML . | ||
|---|---|---|---|
| . | mRNA Expression . | ||
| . | α1−/α2− . | α1+/α2− . | α1+/α2+ . |
| Total cases | 16 (22)3-150 | 35 (49) | 21 (29) |
| Age | |||
| 15-55 | 10 (63) | 26 (74) | 16 (76) |
| >55 | 6 (37) | 9 (26) | 5 (24) |
| Sex | |||
| Male | 6 (37) | 17 (49) | 13 (62) |
| Female | 10 (63) | 18 (51) | 8 (38) |
| Race | |||
| White | 13 (81) | 30 (86) | 21 (100) |
| Nonwhite | 3 (19) | 5 (14) | 0 (0) |
| Performance status | |||
| 0-1 | 14 (88) | 28 (80) | 20 (95) |
| >1 | 2 (12) | 7 (20) | 1 (5) |
| Clinical signs of bleeding disorder | |||
| No | 6 (37) | 8 (23) | 9 (43) |
| Yes | 10 (63) | 27 (77) | 12 (57) |
| Characteristic or Category . | RARα-PML . | ||
|---|---|---|---|
| . | mRNA Expression . | ||
| . | α1−/α2− . | α1+/α2− . | α1+/α2+ . |
| Total cases | 16 (22)3-150 | 35 (49) | 21 (29) |
| Age | |||
| 15-55 | 10 (63) | 26 (74) | 16 (76) |
| >55 | 6 (37) | 9 (26) | 5 (24) |
| Sex | |||
| Male | 6 (37) | 17 (49) | 13 (62) |
| Female | 10 (63) | 18 (51) | 8 (38) |
| Race | |||
| White | 13 (81) | 30 (86) | 21 (100) |
| Nonwhite | 3 (19) | 5 (14) | 0 (0) |
| Performance status | |||
| 0-1 | 14 (88) | 28 (80) | 20 (95) |
| >1 | 2 (12) | 7 (20) | 1 (5) |
| Clinical signs of bleeding disorder | |||
| No | 6 (37) | 8 (23) | 9 (43) |
| Yes | 10 (63) | 27 (77) | 12 (57) |
P ≥ .1 for all categories.
No. of cases (% of cases).